Private equity funds managed by Blackstone () have entered into a definitive agreement to acquire contract research organization (CRO) Nucleus Network from Australian private equity firm Crescent Capital.
The value of the transaction was not disclosed. For its part, Melbourne-based Crescent Capital acquired Nucleus Network in 2018 from the Baker Heart and Diabetes Institute, an independent medical research institute, also for an undisclosed amount.
Nucleus Network conducts outsourced Phase I clinical trials -- the earliest-stage trials in humans -- for clients in the pharmaceutical and biotechnology industries. The company bills itself as Australia's largest CRO . . .
Unlock this article instantly, along with the rest of our premium content, newsletters and data tables tracking investor and manager activity. Monthly and annual subs available. Research articles require an Annual sub.